Nature Publishes Discovery And Preclinical Results For ABBV-CLS-484, A Potential First-In-Class PTPN2/N1 Inhibitor In Cancer Immunotherapy
Portfolio Pulse from Benzinga Newsdesk
AbbVie, the Broad Institute of MIT and Harvard, and Calico Life Sciences have announced the publication of preclinical data for ABBV-CLS-484, a potential first-in-class, orally bioavailable, PTPN2/N1 phosphatase inhibitor that enhances anti-tumor immunity. The findings support the development of ABBV-CLS-484 as a promising new strategy for cancer immunotherapy. ABBV-CLS-484 is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.
October 04, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's ABBV-CLS-484, a potential first-in-class cancer immunotherapy, has shown promising preclinical data. The drug is currently in Phase 1 clinical trials.
The news of promising preclinical data for ABBV-CLS-484, a potential first-in-class cancer immunotherapy, is likely to be positively received by the market. This could potentially lead to an increase in AbbVie's stock price in the short term. The fact that the drug is already in Phase 1 clinical trials further strengthens this potential positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100